Cargando…

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and full-term infants in the phase 2b and phase 3 MELODY trials. We analyzed serum samples collected from 2,143 infant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkins, Deidre, Yuan, Yuan, Chang, Yue, Aksyuk, Anastasia A., Núñez, Beatriz Seoane, Wählby-Hamrén, Ulrika, Zhang, Tianhui, Abram, Michael E., Leach, Amanda, Villafana, Tonya, Esser, Mark T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202809/ https://www.ncbi.nlm.nih.gov/pubmed/37095249 http://dx.doi.org/10.1038/s41591-023-02316-5

Ejemplares similares

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
por: Ahani, Bahar, et al.
Publicado: (2023)

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
por: Domachowske, Joseph B, et al.
Publicado: (2023)

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
por: Wilkins, Deidre, et al.
Publicado: (2023)

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
por: Morehouse, Christopher A, et al.
Publicado: (2023)

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
por: Hammitt, Laura, et al.
Publicado: (2021)

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants
por: Abram, Michael E, et al.
Publicado: (2022)

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model
por: Voirin, Nicolas, et al.
Publicado: (2021)

89. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
por: Faust, Saul N, et al.
Publicado: (2023)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
por: Kieffer, Alexia, et al.
Publicado: (2022)

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
por: Turalde-Mapili, Maria Wilma R., et al.
Publicado: (2023)

Characterization of Circulating RSV Strains Among Patients In The Outsmart RSV Program During the 2015–16 Winter Viral Season in the United States
por: Pastula, Susan, et al.
Publicado: (2017)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019)

Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States
por: Ruzin, Alexey, et al.
Publicado: (2018)

Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017−2018 INFORM-RSV Study
por: Tabor, David E., et al.
Publicado: (2020)

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
por: Simões, Eric A F, et al.
Publicado: (2023)

Is it RSV?
por: Ambrose, Christopher S.
Publicado: (2018)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
por: Brady, Tyler, et al.
Publicado: (2023)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2022)

A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
por: Domachowske, Joseph B, et al.
Publicado: (2017)

An outbreak of RSV infections in a neonatology clinic during the RSV-season
por: Vakrilova, Liliya, et al.
Publicado: (2021)

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age
por: Malkin, Elissa, et al.
Publicado: (2013)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

Correction: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV
por: Cullen, Lori M., et al.
Publicado: (2017)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
por: Chee, Chris, et al.
Publicado: (2010)

Characterization of human respiratory syncytial virus (RSV) isolated from HIV‐exposed‐uninfected and HIV‐unexposed infants in South Africa during 2015‐2017
por: Liu, Hui, et al.
Publicado: (2020)

Immunity to RSV in Early-Life
por: Lambert, Laura, et al.
Publicado: (2014)

Severe Rhabdomyolysis Associated With RSV
por: Bender, James, et al.
Publicado: (2017)

Nasal Microbiota in RSV Bronchiolitis
por: Schippa, Serena, et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

Socioeconomic Impact of RSV Hospitalization
por: Young, Michal, et al.
Publicado: (2021)

Immunopathology of RSV: An Updated Review
por: Bergeron, Harrison C., et al.
Publicado: (2021)

Clinical severity of RSV bronchiolitis
por: Hussain, Faris, et al.
Publicado: (2022)

Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity
por: D’Sa, Sucheta, et al.
Publicado: (2022)

260. Durability of Antibody Responses to RSV in Older Adults Following Hospitalization for Acute Respiratory Infection
por: Ciric, Caroline, et al.
Publicado: (2023)

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fe623u301hnsmpupun4h48f9un